SEC Form 4 · accession 0001104659-26-075249
Zenas BioPharma, Inc. · ZBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer A. Fox
Officer — See Remarks
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 6:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001953926
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 5, 2026 | A | 1,592 | $13.35 | A | 1,592 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $18.71 | Jun 15, 2026 | A | 125,000 | A | — | Jun 15, 2036 | Common Stock | 125,000 | 125,000 | D |
Explanation of responses
- F1Common Stock acquired under Zenas BioPharma, Inc.'s 2024 Employee Stock Purchase Plan on February 5, 2026 in transactions that were exempt under Rule 16b-3(c).
- F2The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.
Remarks
Chief Business Officer and Chief Financial Officer